[go: up one dir, main page]

BRPI0418769A - composição farmacêutica compreendendo cefixima, processo para a preparação de uma forma de dosagem oral sólida compreendendo de partìculas de cefixima, método para conseguir bio-equivalência entre a forma de dosagem oral e uma suspensão e comprimido mastigável compreendendo cefixima - Google Patents

composição farmacêutica compreendendo cefixima, processo para a preparação de uma forma de dosagem oral sólida compreendendo de partìculas de cefixima, método para conseguir bio-equivalência entre a forma de dosagem oral e uma suspensão e comprimido mastigável compreendendo cefixima

Info

Publication number
BRPI0418769A
BRPI0418769A BRPI0418769-5A BRPI0418769A BRPI0418769A BR PI0418769 A BRPI0418769 A BR PI0418769A BR PI0418769 A BRPI0418769 A BR PI0418769A BR PI0418769 A BRPI0418769 A BR PI0418769A
Authority
BR
Brazil
Prior art keywords
cefixime
oral dosage
dosage form
preparing
chewable tablet
Prior art date
Application number
BRPI0418769-5A
Other languages
English (en)
Inventor
Sanjay Wagh
Hidaytulla Aga
Makarand Avachat
Sen Himadri
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of BRPI0418769A publication Critical patent/BRPI0418769A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIçãO FARMACêUTICA COMPREENDENDO CEFIXIMA, PROCESSO PARA A PREPARAçãO DE UMA FORMA DE DOSAGEM ORAL SóLIDA COMPREENDENDO DE PARTìCULAS DE CEFIXIMA, MéTODO PARA CONSEGUIR BIO-EQUIVALêNCIA ENTRE A FORMA DE DOSAGEM ORAL E UMA SUSPENSãO E COMPRIMIDO MASTIGáVEL COMPREENDENDO CEFIXIMA A presente invenção refere-se a um comprimido mastigável compreendendo Cefixima tendo um tamanho médio de partícula entre 20 <109> e 120 <109> no qual a referida composição demonstra uma bio equivalência a uma suspensão de trihidrato de Cefixima. O processo de preparação do comprimido mastiqável compreende as etapas de micronizar a Cefixima, opcionalmente, de tal maneira que o tamanho médio de partícula das partículas de Cefixima seja entre 20 <109> e 120 <109>, mesclando com outros excipientes, compactando a rolo, moendo para formar grânulos, mesclando para formar uma mescla secundária e comprimindo a mescla secundária para formar os comprimidos.
BRPI0418769-5A 2004-05-10 2004-05-10 composição farmacêutica compreendendo cefixima, processo para a preparação de uma forma de dosagem oral sólida compreendendo de partìculas de cefixima, método para conseguir bio-equivalência entre a forma de dosagem oral e uma suspensão e comprimido mastigável compreendendo cefixima BRPI0418769A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2004/000128 WO2005107703A1 (en) 2004-05-10 2004-05-10 Novel pharmaceutical formulation of cefixime for enhanced bioavailability

Publications (1)

Publication Number Publication Date
BRPI0418769A true BRPI0418769A (pt) 2007-10-09

Family

ID=34958567

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418769-5A BRPI0418769A (pt) 2004-05-10 2004-05-10 composição farmacêutica compreendendo cefixima, processo para a preparação de uma forma de dosagem oral sólida compreendendo de partìculas de cefixima, método para conseguir bio-equivalência entre a forma de dosagem oral e uma suspensão e comprimido mastigável compreendendo cefixima

Country Status (5)

Country Link
US (2) US9149482B2 (pt)
JP (1) JP2007536378A (pt)
BR (1) BRPI0418769A (pt)
MX (1) MXPA06012944A (pt)
WO (1) WO2005107703A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113968874A (zh) * 2021-10-29 2022-01-25 国药集团威奇达药业有限公司 头孢克肟的精制方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007536378A (ja) 2004-05-10 2007-12-13 ルピン・リミテッド 生体利用性が強化されている新規セフィキシム医薬製剤
CN103735524B (zh) * 2013-12-30 2015-10-21 海南葫芦娃制药有限公司 一种头孢克肟咀嚼片及其制备方法
CN113662919B (zh) * 2021-09-18 2022-10-11 海南鑫开源医药科技有限公司 一种稳定的头孢克肟片剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409214A (en) * 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
US4569852A (en) * 1983-08-23 1986-02-11 Warner-Lambert Company Maintenance of flavor intensity in pressed tablets
US4525341A (en) * 1984-04-09 1985-06-25 Mayor Pharmaceutical Laboratories, Inc. Method of administering vitamins
FR2669221B1 (fr) * 1990-11-15 1993-01-15 Rhone Poulenc Sante Procede de preparation par compression directe de comprimes de derives de l'acide cephalosporanique.
DE4418957A1 (de) * 1994-05-31 1995-12-07 Merck Patent Gmbh Cefixim-Zubereitung
DK0890359T3 (da) * 1996-02-29 2002-07-01 Fujisawa Pharmaceutical Co Beta-Lactam-antibiotikumholdige tabletter og fremgangsmåde til fremstilling deraf
US6080427A (en) 1997-04-17 2000-06-27 Bristol-Myers Squibb Company Cefadroxil monohydrate tablet formulation
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2374760A1 (en) * 1999-06-18 2000-12-28 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
JP2001058944A (ja) * 1999-06-18 2001-03-06 Takeda Chem Ind Ltd 速崩壊性固形製剤
FR2814679B1 (fr) * 2000-09-29 2003-04-11 Cll Pharma Compositions pharmaceutiques dispersibles a base de cephalosporines, leur procede de preparation et leur utilisation
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
JP4526247B2 (ja) * 2002-07-08 2010-08-18 第一三共株式会社 経口用セファロスポリン製剤
JP2007536378A (ja) 2004-05-10 2007-12-13 ルピン・リミテッド 生体利用性が強化されている新規セフィキシム医薬製剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113968874A (zh) * 2021-10-29 2022-01-25 国药集团威奇达药业有限公司 头孢克肟的精制方法

Also Published As

Publication number Publication date
US9149482B2 (en) 2015-10-06
US20070286901A1 (en) 2007-12-13
WO2005107703A1 (en) 2005-11-17
MXPA06012944A (es) 2007-02-12
JP2007536378A (ja) 2007-12-13
US20140171401A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
HRP20200046T1 (hr) Formulacije apiksabana
BRPI0707044B8 (pt) comprimido matricial insolúvel em água e processo de fabricação de comprimidos matriciais
JP2005507881A5 (pt)
BRPI0413394A8 (pt) Formulação de lantânio mastigável em tablete, formulação farmacêutica em tablete ou em pó, método para tratar hiperfosfatemia, uso de uma quantidade terapeuticamente efetiva de uma formulação de um composto de lantânio, processo para preparar uma formulação em tablete de um composto de lantânio
NZ592276A (en) PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY(epsilon-CAPROLACTONE) AND AN OPIOID
DOP2006000241A (es) Composiciones farmacéuticas sólidas que contienen pregabalina
MX2008001645A (es) Composiciones de fexofendina en suspension farmaceutica oral.
IL192374A0 (en) Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
BRPI0608853B8 (pt) composições farmacêuticas e processo para a fabricação de microgrânulos de rifaximina gastrorresistentes
CN1358090A (zh) 左旋多巴/卡比多巴/恩他卡朋药物制剂
EA200100024A1 (ru) Состав таблетки с делавирдином
DE60306120D1 (de) Pharmazeutische formulierung, die n-((1-n-butyl-4-piperidinyl)menthyl)-3,4-dihydro-2h-(1,3)oxazino(3,2-a)indol-10-carboxamid oder ein entsprechendes salz hiervon enthält, sowie deren herstellungsprozess, welcher trockengranulierung beinhaltet
AR105184A1 (es) Comprimidos de liberación inmediata que contienen un fármaco y procesos para formar los comprimidos
DE60314265D1 (de) Pharmazeutische zusammensetzungen mit modafinil
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
CA2535013A1 (en) Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
Naik et al. Formulation and evaluation of Oxybutynin chloride extended release matrix tablets
BRPI0418769A (pt) composição farmacêutica compreendendo cefixima, processo para a preparação de uma forma de dosagem oral sólida compreendendo de partìculas de cefixima, método para conseguir bio-equivalência entre a forma de dosagem oral e uma suspensão e comprimido mastigável compreendendo cefixima
RU2008152184A (ru) Способ получения мультичастиц с применением роликового компактора
WO2008100240A3 (en) Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
BRPI0518789A2 (pt) formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete
UA105648C2 (uk) Екструдати з голчатими активними речовинами
WO2006041843A3 (en) Pharmaceutical dosage form comprising meloxicam
BRPI0518786A2 (pt) formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete
BRPI0518790A2 (pt) formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A E 7A ANUIDADE(S)

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.